Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company develops a Phase Ib/II ISS with rigosertib monotherapy in patients with advanced squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa; and has a preclinical program comprising IV/oral rigosertib for COVID-19. It has a license agreement with SymBio Pharmaceuticals Limited; license, development, and commercialization agreement with Pint International SA.; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
P/E ratio for Onconova Therapeutics, Inc. (ONTX)
P/E ratio as of 2023: -0.83
According to Onconova Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.83. At the end of 2022 the company had a P/E ratio of -0.74.
P/E ratio history for Onconova Therapeutics, Inc. from 2011 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -0.83 |
| 2022 | -0.74 |
| 2021 | -2.71 |
| 2020 | -3.25 |
| 2019 | -0.25 |
| 2018 | -0.59 |
| 2017 | -0.56 |
| 2016 | -0.51 |
| 2015 | -0.91 |
| 2014 | -1.12 |
| 2013 | -1.94 |
| 2012 | -10.26 |
| 2011 | -11.68 |